In this case study, Dr David Gervais, Head of Product and Fermentation Development at Porton Biopharma describes how a non-GMP enzyme manufacturing process has been successfully converted from a native to a recombinant one using bioinformatics and next-generation sequencing (NGS).
Demonstrating PBL’s capability to deliver significant improvements in yield, purity and activity for customer’s products.
Porton Biopharma will be attending the Salisbury Jobs fair in the Guildhall on Tuesday 2nd April. Do come along and see us between 9am and 3pm to find out more about what we do and our exciting range of careers.
PBL will be attending the Innovation in manufacturing through collaboration event in Darlington on Wednesday 27th March, as well as the Bioprocess International Europe conference 2019 conference in Vienna from 2-5th April.
In advance of next week’s National Apprenticeship Week Porton Biopharma Ltd (PBL) is excited to announce that we have recruited our first apprentice, Will Tucker. Joining the company as a full-time employee from the end of February he’ll be enrolled on a five year programme leading to a BSC in applied biology.
PBL has issued a statement regarding the Royalty Bearing Licence Agreement with Jazz Pharmaceuticals for the distribution of Erwinase. The statement can be read here:
PBL is featured in a technical article in Manufacturing Chemist on “Automating the production of life-saving drugs” in regards to the new Bosch integrated filling line that we have installed to meet the growing demand for our Erwinase product, which is used to treat childhood leukaemia.
Porton Biopharma Ltd is very pleased to announce the appointment of a new non-executive Chair for the Company, Barry Clare. Barry is a pioneering healthcare business leader with extensive experience in the healthcare industry and an experienced non-executive director and company chair.
Porton Biopharma staff will be attending and presenting at a number of international conferences this autumn and we would be delighted to speak to you about our capabilities.